Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Developme... ( SAN DIEGO May 12 /- Cardium Therapeut...)

HOME >> BIOLOGY >> TECHNOLOGY

Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program

Date:5/12/2009

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of its Excellarate product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes. In addition, on May 7, 2009, Cardium announced significant new formulation enhancements for Excellarate that are designed to simplify and broaden the use of the product candidate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and serious trauma wounds.

Cardium will hold a live conference call and webcast Thursday, May 14, 2009 at 4:30 p.m. (Eastern). Participants can access the live conference call by dialing 866-202-1971(US) or 617-213-8842 (International) using the conference passcode 37347570. The call and accompanying slides can also be accessed via the webcast through the Company's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.

If you are unable to attend the webcast a replay of the
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems

Post Your Comments:

Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Developme...( SAN DIEGO May 12 /- Cardium Therapeut...)